Cartesian Therapeutics In... (RNAC)
Cartesian Therapeutics Statistics
Share Statistics
Cartesian Therapeutics has 25.91M shares outstanding. The number of shares has increased by 45.58% in one year.
| Shares Outstanding | 25.91M |
| Shares Change (YoY) | 45.58% |
| Shares Change (QoQ) | 0.71% |
| Owned by Institutions (%) | 4.19% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 25,330 |
| FTD / Avg. Volume | 26.75% |
Short Selling Information
The latest short interest is 2.38M, so 9.2% of the outstanding shares have been sold short.
| Short Interest | 2.38M |
| Short % of Shares Out | 9.2% |
| Short % of Float | 14.49% |
| Short Ratio (days to cover) | 14.64 |
Valuation Ratios
The PE ratio is -35.88 and the forward PE ratio is -3.4. Cartesian Therapeutics's PEG ratio is 0.36.
| PE Ratio | -35.88 |
| Forward PE | -3.4 |
| PS Ratio | 71.39 |
| Forward PS | 2.8 |
| PB Ratio | -408.41 |
| P/FCF Ratio | -84.78 |
| PEG Ratio | 0.36 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Cartesian Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.43, with a Debt / Equity ratio of -2.06.
| Current Ratio | 9.43 |
| Quick Ratio | 9.43 |
| Debt / Equity | -2.06 |
| Debt / EBITDA | -0.18 |
| Debt / FCF | -0.43 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $589,590.91 |
| Profits Per Employee | $-1,173,090.91 |
| Employee Count | 66 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 287K |
| Effective Tax Rate | -0.37% |
Stock Price Statistics
The stock price has increased by -49.53% in the last 52 weeks. The beta is 0.5, so Cartesian Therapeutics's price volatility has been higher than the market average.
| Beta | 0.5 |
| 52-Week Price Change | -49.53% |
| 50-Day Moving Average | 14.48 |
| 200-Day Moving Average | 17.2 |
| Relative Strength Index (RSI) | 48.56 |
| Average Volume (20 Days) | 94,698 |
Income Statement
In the last 12 months, Cartesian Therapeutics had revenue of 38.91M and earned -77.42M in profits. Earnings per share was -0.5.
| Revenue | 38.91M |
| Gross Profit | 38.91M |
| Operating Income | -43.9M |
| Net Income | -77.42M |
| EBITDA | -75.99M |
| EBIT | -77.14M |
| Earnings Per Share (EPS) | -0.5 |
Balance Sheet
The company has 212.61M in cash and 13.98M in debt, giving a net cash position of 198.63M.
| Cash & Cash Equivalents | 212.61M |
| Total Debt | 13.98M |
| Net Cash | 198.63M |
| Retained Earnings | -692.07M |
| Total Assets | 435.02M |
| Working Capital | 193.65M |
Cash Flow
In the last 12 months, operating cash flow was -23.67M and capital expenditures -9.09M, giving a free cash flow of -32.77M.
| Operating Cash Flow | -23.67M |
| Capital Expenditures | -9.09M |
| Free Cash Flow | -32.77M |
| FCF Per Share | -0.21 |
Margins
Gross margin is 100%, with operating and profit margins of -112.81% and -198.97%.
| Gross Margin | 100% |
| Operating Margin | -112.81% |
| Pretax Margin | -198.23% |
| Profit Margin | -198.97% |
| EBITDA Margin | -195.27% |
| EBIT Margin | -112.81% |
| FCF Margin | -84.21% |
Dividends & Yields
RNAC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for RNAC is $41, which is 232.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $41 |
| Price Target Difference | 232.5% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Stock Splits
The last stock split was on Apr 5, 2024. It was a backward split with a ratio of 1:30.
| Last Split Date | Apr 5, 2024 |
| Split Type | backward |
| Split Ratio | 1:30 |
Scores
| Altman Z-Score | -1.76 |
| Piotroski F-Score | 3 |